Skip to main content

ImmunID, Singapore Immunology Network Collaborate on Immune Study

NEW YORK (GenomeWeb) – French immune molecular diagnostics firm ImmunID on Tuesday announced a deal with the Singapore Immunology Network (SigN) for research into immune competence.

Under the terms of the agreement, ImmunID will use its ImmunTracker and ImmunIG tests to evaluate T and B immune repertoire diversity in the blood of patients enrolled in a SigN-led clinical trial. The indication and therapeutic intervention being studied in the trial were not disclosed.

SigN is a research institute under Singapore's Agency of Science, Technology, and Research.

Anis Larbi, the principal investigator for the trial, said that ImmunID's technology broadens SigN's research efforts into the human immune system. "We can now get a more comprehensive understanding of it, using parameters such as immune repertoire diversity, which were neglected in the past," he said in a statement.

The project is for two years and will include 180 patients.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.